

**Supplementary Table S2:** Mean relative cellular abundance as estimated by deconvolution analysis. Differences in relative abundances between groups were assessed using Kruskal-Wallis one-way analysis of variance by ranks. When more than 50% of samples lacked data, the cell-type was excluded from analysis.

	CD4+ alpha beta T cell	Memory B cell	Neutrophil	Natural killer cell	Monocyte	B cell	T cell	Granulocyte
<b>Responders</b>								
T0	0.157	0.041	0.338	0.135	0.236	0.047	0.159	0.338
T1	0.179	0.029	0.295	0.160	0.217	0.034	0.185	0.295
<i>P</i> -value T1 vs. T0	0.546	0.182	0.505	0.182	0.182	<b>0.046</b>	0.182	0.505
<b>Nonresponders</b>								
T0	0.159	0.033	0.319	0.158	0.233	0.041	0.180	0.319
T1	0.160	0.028	0.330	0.166	0.234	0.034	0.169	0.331
<i>P</i> -value T1 vs. T0	0.546	0.228	1.000	1.000	0.546	0.227	1.000	1.000
<i>P</i> -value 4-group comparison	0.753	0.627	0.922	0.744	0.962	0.616	0.578	0.915

T0; baseline before initiating vedolizumab. T1; follow up after 10-12 weeks of vedolizumab treatment

The following cells were estimated to very low relative abundance:

CD8+ alpha beta cells were detected in 4/9 responders and in 4/11 non-responders.

Naïve B-cells were detected in 1/9 responders and in 7/11 non-responders.

Plasma cells were detected in 6/9 responders and in 3/11 non-responders